By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics disclosed after the close of the market on Thursday that it has been told by Nasdaq that it falls short of a listing requirement and could face delisting.

In a document filed with the US Securities Exchange Commission, the Israeli firm said it received a letter from Nasdaq on Dec. 6 saying its stockholders' equity had fallen below the minimum $2.5 million required to remain listed on the Nasdaq Capital market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.